Abdominal Pain Clinical Trial
Official title:
A Pilot Study to Assess the Potential Value of Adding Endoscopic Ultrasound (EUS) to Esophago-gastro-duodenoscopy (EGD) in Emergency Room Patients Referred for Egd
Emergency room patients referred for esophago-gastro-duodenoscopy (EGD) often have many possible causes for their symptoms. These inevitably undergo further testing if EGD is inconclusive, which adds costs and inevitably prolongs emergency room length of stay (LOS).EUS has traditionally been used after EGD for a myriad of costs reasons that no longer apply. We therefore propose a prospective pilot study to determine whether PEUS can reduce LOS and resource utilisation in emergency room patients referred for EGD.
A PILOT STUDY TO ASSESS THE POTENTIAL VALUE OF ADDING ENDOSCOPIC ULTRASOUND (EUS) TO
ESOPHAGO-GASTRO-DUODENOSCOPY (EGD) IN EMERGENCY ROOM PATIENTS REFERRED FOR EGD
P.I.: Anand V. Sahai MD, MSc (EPID), FRCPC
BACKGROUND Emergency room patients referred for esophago-gastro-duodenoscopy (EGD) often have
many possible causes for their symptoms. These inevitably undergo further testing if EGD is
inconclusive, which adds costs and inevitably prolongs emergency room length of stay (LOS).
Endoscopic ultrasound (EUS) combines EGD with high-resolution ultrasound imaging of pancreas,
liver and biliary system and is the best test to diagnose bile duct stones, early chronic
pancreatitis, and small [<2cm] pancreatic cancers (all of which cannot be seen by regular
ultrasound or CT scanning or MRI, yet are included in the differential diagnosis of
EGD-negative abdominal pain).
EUS has traditionally been used after EGD, due to lack of availability, increased cost, and
to increased risk due to larger scope diameter. However, the latest generation of EUS scopes
have the same outer diameter as conventional gastroscopes, there is much wider availability
of EUS in university and community hospital settings, and the cost per procedure is lower,
due to increased procedural numbers and reduced maintenance costs.
In experienced hands, diagnostic EUS is now as safe and as EGD accurate as EGD for diagnosing
mucosal pathology and takes approximately 1 minute longer.(1; 2) Previously published work by
our group suggests that EUS may reduce resource consumption in patients with unexplained
abdominal pain.(3) The investigators also showed that refractory dyspepsia with normal EGD
and CT, EUS identified signs of occult chronic pancreatitis in up to 20% of cases.(4) More
recently, EUS was found to identify previously undiagnosed, potential causes of unexplained
abdominal pain in up to 9% of patients, or at least provides the same, if not more
information and EGD and abdominal US alone.(2; 5; 6) There are no previous studies that have
prospectively compared the yield of EGD and PEUS in emergency room patients. The
investigators hypothesize that adding EUS to EGD ("primary EUS" [PEUS]) can safely and more
efficiently diagnose or exclude significant gastro-intestinal and pancreatico-biliary
pathology in emergency room patients in whom EGD has been requested. The investigators
therefore propose a prospective pilot study to determine whether PEUS can reduce LOS and
resource utilisation in emergency room patients referred for EGD.
AIM To perform a pilot study to determine whether PEUS reduces emergency room LOS and
resource utilisation in emergency room patients referred for EGD.
METHODS
Study design This is an open-label two-arm, single center, superiority trial with 1:1
allocation ratio between EUS and standard intervention EGD.
Site
This study will be performed at the St Luc site of CHUM. Approximately 5000 EGD procedures
and 3000 EUS procedures are performed at this site annually. Therefore, there should be
sufficient eligible patients for efficient patient recruitment.
Research team A research team composed of the PI, one research nurse, and a biostatistician
will coordinate the trial. The research assistant will be responsible for all data collection
and patient recruitment (including consent). Statistical analysis will be provided by the
biostatistical platform of the CR-CHUM under the supervision of Dr Martin Ladouceur.
Funding There is no external funding for this study.
Patient selection All patients referred for GI consultation in the emergency room at CHUM,
site St Luc, are eligible.
Inclusion Criteria EGD requested by the consulting gastroenterologist Informed consent
Exclusion criteria Evidence of hemodynamic instability and/or ongoing active GI bleeding. Any
suspicion of obstruction distal to the angle of Treitz. EGD or EUS cannot be performed before
12PM. Previous barium study, EGD, US, abdomino-pelvic CT, or abdomino-pelvic MRI within the
last 6 months.
After the EGD request form is received in the GI department, the patient will be transported
as usual to the endoscopy unit. Before entering an endoscopy suite, a single research
assistant will present the patients the study protocol. After informed consent, each group
will be randomized by sealed envelop to EGD or to PEUS. A gastroenterologist other than the
one who requested EGD will perform EGD or EUS. Written EGD and PEUS reports will be presented
in the standard fashion.
EGD and EUS are both available every day, before 12PM. They will be performed and interpreted
by experienced operators (not fellows).
OUTCOMES
Patients in whom EGD is scheduled after GI consultation will be stratified in to 2 groups:
1. abdominal pain syndromes (defined as any pain or discomfort considered to be possibly of
GI origin)
2. all other indications.
Primary outcome The primary outcome will be "time to GI diagnosis" (with T0 starting
immediately after the procedure report is read and signed by the referring physician). A "GI
diagnosis" is defined as diagnosis or confirmation of any condition sufficient to start
treatment or to modify the existing therapeutic regimen.
Secondary outcomes
Secondary outcomes will be:
frequency of conversion to the alternate procedure (EGD to EUS, or EUS to EGD) number of
subsequent imaging procedures other than endoscopy complications (defined as any event that
prolongs hospital stay)
SAMPLE SIZE CALCULATIONS Given the novelty of the primary outcome of this study ("time to
diagnosis, discharge, or admission"), there are no reliable data on which a sample-size
estimate can be calculated. The investigators propose a pilot approach, with 40 patients per
randomisation group (80 patients in total). This would be followed by an analysis to further
clarify the appropriate sample size.
4.4 Expected Duration of Study Given our current patient volumes, the investigatorsshould be
able to recruit 1 person per day (5 per week). This should require approximately 16 weeks (4
months) to complete this pilot project. Given that the primary endpoint is likely to occur in
less than 3-4 days, the entire study duration until complete follow of the last patient would
be approximately 17 weeks. To be conservative, and allow for unexpected contingencies, we
propose an estimate for pilot study duration of 8 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04682860 -
Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide
|
Phase 4 | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02547857 -
Transvaginal Pelvic Ultrasound in the ED
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02923245 -
POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound
|
N/A | |
Completed |
NCT02676232 -
DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Terminated |
NCT01410071 -
Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction
|
N/A | |
Terminated |
NCT01736280 -
Evaluating and Treating Potential Research Participants With Digestive Disorders
|
N/A | |
Enrolling by invitation |
NCT04104867 -
Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy
|
N/A | |
Completed |
NCT03574727 -
Abdominal Cutaneous Nerve Entrapment Syndrome
|
||
Completed |
NCT04614649 -
Right Iliac Fossa Treatment-Turkey Audit
|
||
Completed |
NCT05438654 -
Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain
|
N/A | |
Completed |
NCT06423586 -
Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
|
N/A | |
Completed |
NCT03558009 -
Epidemiological Analysis for Hereditary Angioedema Disease
|
||
Terminated |
NCT03148288 -
Vitamin D Supplementation in IBS
|
N/A | |
Completed |
NCT03708874 -
Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
|
||
Withdrawn |
NCT04408872 -
EUS vs EGD in Emergency Room Patients Referred for EGD
|
N/A | |
Recruiting |
NCT02594774 -
Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents
|
N/A |